Ken Fisher
ADMS

Ken Fisher’s Adamas Pharmaceuticals ADMS Stock Holding History

Ken Fisher’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-59,771
Closed -$316K – 976
2021
Q2 		$316K Buy
59,771
+22,279
+59% +$115K ﹤0.01% 795
2021
Q1 		$180K Buy
37,492
+1,342
+4% +$7.01K ﹤0.01% 868
2020
Q4 		$157K Sell
36,150
-22,840
-39% -$97.7K ﹤0.01% 885
2020
Q3 		$243K Buy
58,990
+27
+0% +$104 ﹤0.01% 779
2020
Q2 		$151K Hold
58,963
– – ﹤0.01% 787
2020
Q1 		$170K Hold
58,963
– – ﹤0.01% 737
2019
Q4 		$223K Sell
58,963
-79,761
-57% -$382K ﹤0.01% 776
2019
Q3 		$710K Hold
138,724
– – ﹤0.01% 642
2019
Q2 		$860K Buy
138,724
+22,705
+20% +$131K ﹤0.01% 613
2019
Q1 		$825K Sell
116,019
-5,440
-4% -$48.9K ﹤0.01% 597
2018
Q4 		$1.04M Buy
121,459
+3,342
+3% +$43.5K ﹤0.01% 596
2018
Q3 		$2.37M Sell
118,117
-28,012
-19% -$658K ﹤0.01% 508
2018
Q2 		$3.77M Buy
146,129
+109,698
+301% +$3.04M ﹤0.01% 467
2018
Q1 		$871K Hold
36,431
– – ﹤0.01% 579
2017
Q4 		$1.24M Sell
36,431
-75
-0.2% -$2.09K ﹤0.01% 564
2017
Q3 		$773K Buy
+36,506
New +$669K ﹤0.01% 585

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ken Fisher's ADMS Position: Q3 2021 in Review

Ken Fisher sold out of Adamas Pharmaceuticals (ADMS) in Q3 2021, closing a stake of 59,771 shares — an estimated $316K sold.

Ken Fisher first reported a position in ADMS in Q3 2017 and held it in 16 quarters. The position peaked at $3.77M in Q2 2018. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2021.

  • Ken Fisher reported no remaining Adamas Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Ken Fisher sold 59,771 Adamas Pharmaceuticals shares in Q3 2021, an estimated $316K.
  • Ken Fisher first reported a position in Adamas Pharmaceuticals in Q3 2017 and held it in 16 quarters.
  • Ken Fisher's Adamas Pharmaceuticals position peaked at $3.77M in Q2 2018.
  • 63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2021.

Based on Fisher Asset Management's 13F filing for Q3 2021, filed 26 Oct 2021.